Greenwich LifeSciences, Inc. (GLSI)
18.38
-0.21
(-1.13%)
USD |
NASDAQ |
Sep 29, 16:00
18.50
+0.12
(+0.65%)
After-Hours: 20:00
Greenwich LifeSciences Enterprise Value : 260.91M for Sept. 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | 260.91M |
| September 28, 2026 | 263.99M |
| September 25, 2026 | 258.56M |
| September 24, 2026 | 256.80M |
| September 23, 2026 | 248.14M |
| September 22, 2026 | 277.05M |
| September 21, 2026 | 264.06M |
| September 18, 2026 | 269.86M |
| September 17, 2026 | 261.06M |
| September 16, 2026 | 220.54M |
| September 15, 2026 | 227.30M |
| September 14, 2026 | 226.71M |
| September 11, 2026 | 217.90M |
| September 10, 2026 | 212.18M |
| September 09, 2026 | 211.74M |
| September 08, 2026 | 224.51M |
| September 04, 2026 | 225.24M |
| September 03, 2026 | 220.54M |
| September 02, 2026 | 222.16M |
| September 01, 2026 | 211.44M |
| August 31, 2026 | 210.56M |
| August 28, 2026 | 221.13M |
| August 27, 2026 | 266.05M |
| August 26, 2026 | 258.71M |
| August 25, 2026 | 263.99M |
| Date | Value |
|---|---|
| August 24, 2026 | 249.17M |
| August 21, 2026 | 235.81M |
| August 20, 2026 | 215.85M |
| August 19, 2026 | 245.64M |
| August 18, 2026 | 244.47M |
| August 17, 2026 | 246.23M |
| August 14, 2026 | 237.72M |
| August 13, 2026 | 231.55M |
| August 12, 2026 | 239.48M |
| August 11, 2026 | 219.37M |
| August 10, 2026 | 218.64M |
| August 07, 2026 | 201.90M |
| August 06, 2026 | 200.14M |
| August 05, 2026 | 202.34M |
| August 04, 2026 | 201.76M |
| August 03, 2026 | 189.87M |
| July 31, 2026 | 189.28M |
| July 30, 2026 | 196.91M |
| July 29, 2026 | 179.00M |
| July 28, 2026 | 188.55M |
| July 27, 2026 | 188.40M |
| July 24, 2026 | 181.65M |
| July 23, 2026 | 184.73M |
| July 22, 2026 | 185.90M |
| July 21, 2026 | 206.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 686.13M |
| Amgen, Inc. | 272.33B |
| Anika Therapeutics, Inc. | 253.76M |
| BioCryst Pharmaceuticals, Inc. | 2.595B |
| Imunon, Inc. | 7.210M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.949M |
| Total Expenses (Quarterly) | 3.949M |
| EPS Diluted (Quarterly) | -0.2701 |
| Earnings Yield | -8.25% |
| Normalized Earnings Yield | -8.253 |